Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.70 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.67 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.67 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MMP1 | P03956 | 1/20 | 0.57 |
| ▸ | MMP2 | P08253 | 1/20 | 0.57 |
| ▸ | MMP9 | P14780 | 1/20 | 0.57 |
| ▸ | MMP8 | P22894 | 1/20 | 0.57 |
| ▸ | MMP13 | P45452 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | PKLR | P30613 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11986371 | 1.00 | PKM (0.70) | PKMPTGS2PTGS1CA1CA2 | |
| SCHEMBL7503391 | 0.93 | PTGS2 (0.71) | PKMPTGS2PTGS1 | |
| SCHEMBL8005674 | 0.93 | PKM (0.61) | PKMPTGS2PTGS1CA1CA2 | |
| SCHEMBL14097069 | 0.88 | PTGS2 (0.65) | PKMPTGS2PTGS1 | |
| SCHEMBL13924686 | 0.88 | LMNA (0.60) | PKMPTGS2PTGS1CA1CA2 | |
| SCHEMBL5798973 | 0.88 | PTGS2 (0.60) | PKMPTGS2PTGS1AKR1C3LMNA | |
| SCHEMBL14097066 | 0.88 | PKM (0.73) | PKMPTGS2PTGS1GAAMMP2 | |
| SCHEMBL3468454 | 0.86 | AKR1C3 (0.61) | PKMPTGS2PTGS1GAAAKR1C3 | |
| SCHEMBL6725826 | 0.84 | PTGS2 (0.77) | PTGS2PTGS1 | |
| SCHEMBL31384620 | 0.84 | PTGS2 (0.53) | PKMPTGS2PTGS1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118763273-A | Sulfonyl deep eutectic polymer electrolyte and preparation and application thereof | 青岛赛锂达储能产业技术研究院有限公司 | 2024-10-11 | — | — | CN | claimed |
| CN-104531397-A | Cleaning solution for sheet glass substrate thinning pre-cleaning, and application thereof | HUIJING DISPLAY TECHNOLOGY SUZHOU CO LTD | 2015-04-22 | — | — | CN | claimed |
| CN-102827042-A | Chiral synthesis method of florfenicol | HUBEI MASTEAM BIO TECHNOLOGY CO LTD | 2012-12-19 | — | — | CN | claimed |
| EP-0929519-B1 | BETA-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | UPJOHN CO (US) | 2005-02-23 | — | — | EP | claimed |
| EP-0960108-B1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA ITALIA SPA (IT) | 2004-10-27 | — | — | EP | claimed |
| US-6235928-B1 | ENZYME INHIBITOR MATRIX METALLOPROTEINASE FAMILY, INCLUDING COLLAGENASE, STROMELYSIN, AND GELATINASE, THE COMPOUNDS OR PHARMACEUTICAL COMPOSITIONS | PHARMACIA & UPJOHN COMPANY | 2001-05-22 | — | — | US | claimed |
| US-6194451-B1 | PREVENT RELEASE TUMOR NECROSIS FACTOR; ANTIINFLAMMATORY AGENTS | PHARMACIA & UPJOHN S.P.A. (IT) | 2001-02-27 | — | — | US | claimed |
| EP-0929519-A1 | $g(b)-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-21 | — | — | EP | claimed |
| US-5847153-A | β-sulfonyl hydroxamic acids | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-08 | — | — | US | claimed |
| WO-1998013340-A1 | β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1998-04-02 | — | — | WO | claimed |
| WO-2026099505-A1 | SYSTEM FOR CONTROLLING BATTERY TEMPERATURE | NYOBOLT LIMITED (GB) | 2026-05-15 | — | — | WO | disclosed |
| EP-4634118-B1 | NIOBIUM METAL OXIDE | NYOBOLT LTD (GB) | 2026-04-22 | — | — | EP | disclosed |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12478680-B2 | Hydrogels with biodegradable crosslinking | PROLYNX LLC (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250337004-A1 | COMPOSITE POLYMER CERAMIC ELECTROLYTE | HSBC VENTURES USA INC. | 2025-10-30 | — | — | US | disclosed |
| US-5571660-A | Method for forming an image | KONICA CORPORATION (JP) | 1996-11-05 | — | — | US | disclosed |
| EP-0642055-A1 | A method of forming an image | KONICA CORPORATION (JP) | 1995-03-08 | — | — | EP | disclosed |
| EP-0337063-B1 | Alkyl aryl sulfones and method of preparing the same | ATOCHEM NORTH AMERICA (US) | 1994-04-13 | — | — | EP | disclosed |
| US-5015775-A | Alkyl aryl sulfones and method of preparing the same | ATOCHEM NORTH AMERICA, INC. (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0337063-A1 | Alkyl aryl sulfones and method of preparing the same | ATOCHEM NORTH AMERICA, INC. (a Pennsylvania corp.) (US) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | PKM 3915/4885PTGS2 4049/4885PTGS1 2658/4885 |
| US-12478680-B2 | Hydrogels with biodegradable crosslinking | IDUA, APEH, GUSB | PKM 1638/4885PTGS2 306/4885PTGS1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.